ACCESS Newswire·Nov 11, 2026, 8:30 AM ET

Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder

Protagenic Therapeutics raised $1.5 million in upfront gross proceeds with potential additional proceeds of up to $3.5 million from milestone-linked warrants, totaling $5 million.
Proceeds will fund IND-enabling activities, initiation of the Phase 1/2a trial for PT00114 in Generalized Anxiety Disorder (GAD), working capital, & general corporate purposes.
The IND submission is targeted for late Q1 2027, incorporating FDA pre-IND feedback, with first patient dosing expected in Q2 2027.
Topline safety data is expected in the second half of 2027, while exploratory efficacy data is anticipated in the first half of 2028.
PT00114 is a first-in-class neuropeptide analog of TCAP designed to regulate stress responses, having previously shown safety in non-U.S. Phase 1 studies.
The Phase 1/2a design combines ascending-dose safety cohorts with a GAD patient cohort to assess safety & exploratory efficacy using the Hamilton Anxiety Rating Scale.
Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as the sole placement agent for the private placement financing.